Journal ArticleDOI
Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer
Arlene A. Forastiere,Helmuth Goepfert,Moshe H. Maor,Thomas F. Pajak,Randal S. Weber,William H. Morrison,Bonnie S. Glisson,Andy Trotti,John A. Ridge,C. Chao,Glen Peters,Ding Jen Lee,Andrea Leaf,John F. Ensley,Jay S. Cooper +14 more
TLDR
In patients with laryngeal cancer, radiotherapy with concurrent administration of cisplatin is superior to induction chemotherapy followed by radiotherapy or radiotherapy alone for larynGEal preservation and locoregional control.Abstract:
Background Induction chemotherapy with cisplatin plus fluorouracil followed by radiotherapy is the standard alternative to total laryngectomy for patients with locally advanced laryngeal cancer. The value of adding chemotherapy to radiotherapy and the optimal timing of chemotherapy are unknown. Methods We randomly assigned patients with locally advanced cancer of the larynx to one of three treatments: induction cisplatin plus fluorouracil followed by radiotherapy, radiotherapy with concurrent administration of cisplatin, or radiotherapy alone. The primary end point was preservation of the larynx. Results A total of 547 patients were randomly assigned to one of the three study groups. The median follow-up period was 3.8 years. At two years, the proportion of patients who had an intact larynx after radiotherapy with concurrent cisplatin (88 percent) differed significantly from the proportions in the groups given induction chemotherapy followed by radiotherapy (75 percent, P=0.005) or radiotherapy alone (70 ...read more
Citations
More filters
Journal ArticleDOI
Induction chemotherapy with cisplatin and 5-fluorouracil followed by chemoradiotherapy or radiotherapy alone in the treatment of locoregionally advanced resectable cancers of the larynx and hypopharynx: results of single-center study of 45 patients.
Ozden Altundag,Ibrahim Gullu,Kadri Altundag,Suayib Yalcin,Enis Ozyar,Mustafa Cengiz,Fadil Akyol,Taşkın Yücel,Sefik Hosal,Bülent Sözeri +9 more
TL;DR: Induction chemotherapy with cisplatin and fluorouracil and radiotherapy is an effective alternative to surgery in patients with carcinoma of the larynx and hypopharynx who are treated for organ preservation.
Journal ArticleDOI
Concomitant cisplatin and hyperfractionated radiotherapy in locally advanced head and neck cancer: 10-year follow-up of a randomized phase III trial (SAKK 10/94).
Pirus Ghadjar,Mathew Simcock,Gabriela Studer,Abdelkarim S. Allal,Mahmut Ozsahin,Jacques Bernier,Michael Töpfer,Frank Zimmermann,Michael Betz,Christoph Glanzmann,Daniel M. Aebersold +10 more
TL;DR: After long-term follow-up, combined-treatment with cisplatin and hyperfractionated radiotherapy maintained improved rates of locoregional control, distant metastasis-free survival, and cancer-specific survival compared to that of hyperfracted radiotherapy alone, with no difference in major late toxicity.
Journal ArticleDOI
Altered radiation therapy fractionation, chemoradiation, and patient selection for the treatment of head and neck squamous carcinoma
David I. Rosenthal,K. Kian Ang +1 more
TL;DR: It is proposed that the current standard nonsurgical therapy is the conventional once-daily radiotherapy alone for T1 and favorable T2, N0-1 tumors; altered fractionation alone for unfavorable T2 or exophytic T3, T1-2N2-3 disease; and concurrent chemoradiation for more advanced HNSCCs.
Journal ArticleDOI
New promising molecular targets in head and neck squamous cell carcinoma.
TL;DR: Improved treatment of head and neck squamous cell carcinoma will require a rapid translation of basic science research, and the simultaneous development of novel therapeutics and corresponding biomarkers to guide their application.
Journal ArticleDOI
HNSCC: Tumour Antigens and Their Targeting by Immunotherapy.
Adrian von Witzleben,Adrian von Witzleben,Chuan Wang,Simon Laban,Natalia Savelyeva,Christian H. Ottensmeier,Christian H. Ottensmeier +6 more
TL;DR: The current thinking regarding tumour antigens in HNSCC is reviewed and what has been learned from early phase clinical trials are reviewed.
References
More filters
Book ChapterDOI
Nonparametric Estimation from Incomplete Observations
Edward L. Kaplan,Paul Meier +1 more
TL;DR: In this article, the product-limit (PL) estimator was proposed to estimate the proportion of items in the population whose lifetimes would exceed t (in the absence of such losses), without making any assumption about the form of the function P(t).
Journal Article
Evaluation of survival data and two new rank order statistics arising in its consideration.
Journal ArticleDOI
A Multiple Comparison Procedure for Comparing Several Treatments with a Control
TL;DR: In this article, a multiple comparison procedure for comparing several treatments with a control is presented, which is based on the Multiple Comparison Procedure for Comparing Several Treatments with a Control (MCPC).
Journal ArticleDOI
A Class of $K$-Sample Tests for Comparing the Cumulative Incidence of a Competing Risk
TL;DR: In this paper, a class of tests developed for comparing the cumulative incidence of a particular type of failure among different groups is presented. The tests are based on comparing weighted averages of the hazards of the subdistribution for the failure type of interest.
Journal ArticleDOI
Cancer statistics, 2003.
TL;DR: The American Cancer Society estimates the number of new cancer cases and deaths expected in the United States in the current year, and compiles the most recent data on cancer incidence, mortality, and survival by using incidence data from the National Cancer Institute (NCI) and mortality data from National Center for Health Statistics (NCHS).